Epigenetic Regulation of BDNF in Schizophrenia

Chang Gung Medical Foundation logo

Chang Gung Medical Foundation

Status

Completed

Conditions

BDNF, DNA Methylation, Suicide, Drug Responses.

Study type

Observational

Funder types

Other

Identifiers

NCT01021449
CMRPG870951 and CMRPG870952

Details and patient eligibility

About

In this proposal, we will (1) detect the associations between BDNF and Trk B gene DNA methylation, histone modification, psychotic symptoms, obesity, suicide and antipsychotic drug responses in Taiwanese patients (2) discuss the possible mechanisms of epigenetic regulation of BDNF and Trk B in schizophrenia patients.

Full description

A total 160 subjects (80 subjects every year, including 40 healthy controls and 40 schizophrenia patients) will be recruited during a 2-year period. The first year, the baseline data of BDNF and Trk B DNA methylation, protein and mRNA levels in all subjects will be collected and the following 1 months data will also be collected in schizophrenia with antipsychotic drug treatments. The second year, the baseline data of BDNF and Trk B histone modification in all subjects will be collected.

Enrollment

129 patients

Sex

All

Ages

18 to 65 years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

-

1. The clinical screening and assessment in schizophrenic patients:

  • 40 schizophrenia patients will be recruited in psychiatric inpatients according to DSM-IV criteria (APA, 1994) by a structured interview (SCID). The assessment will be done by two senior psychiatrists. The intra-rater and inter-rater reliability will be done before this project started
  • age : 18-65 years old.
  • The patients had the ability to complete the written inform consent.。
  • The choice of antipsychotic drugs depended on the need of patients in natural treatment procedure. They included conventional drugs, eg.haloperidol 10-20 mg/day;SDA (serotonin dopamine antagonist) drug, eg. clozapine 100-400 mg/day or risperidone 3-6mg/day. The choice of the medication was according to the need of patients including previous responses and side effects.
  • PANSS (Positive and Negative Syndrome)(Kay, 1987,1988&1989) for positive, negative symptoms and severity.
  • Check body mass index (BMI): if BMI<24: normal; 24<BMI<27: overweight; BMI>27: obesity (Taiwan criteria, 2004). If the patients were overweight or obesity, the lipid profiles would be done and we would consult the experts to assess these patients. The condition for diet control and daily activity will be observed. If the condition was extremely abnormal, the case will be excluded.
  • Suicide behavior in tis study includes complete suicide and suicide attempt.

Exclusion criteria

  • The patients had systemic diseases, including metabolic, heart, and liver diseases。
  • The patients had received any drugs before entering this protocol.
  • The patients were heavy smokers or dependent on alcohol.

Trial design

129 participants in 2 patient groups

Control
Description:
Healthy subjects
Schizophrenia
Description:
Schizophrenic patients

Trial contacts and locations

0

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location

Resources

© Copyright 2024 Veeva Systems